Literature DB >> 26732147

A short half-life of ULBP1 at the cell surface due to internalization and proteosomal degradation.

Lola Fernández-Messina1, Hugh T Reyburn1, Mar Valés-Gómez1.   

Abstract

The expression of NKG2D ligands (NKG2D-L) flag stressed cells for immune recognition and destruction. A precise control of the cell surface expression of these proteins is therefore required to ensure an appropriate immune response and it is becoming clear that NKG2D ligand expression is regulated at multiple levels. We now report that the surface stability of the human glycosyl-phosphatidyl-inositol (GPI)-anchored ligand ULBP1 (UL16-binding protein) at the plasma membrane is lower than other ULBP molecules. This difference in stability is due neither to shedding nor to a higher internalization rate of ULBP1 but rather occurs because of a rapid degradation of ULBP1 protein after internalization from the cell surface that is blocked by proteasome inhibition. These data indicate that, in addition to the known transcriptional and post-translational mechanisms, surface expression of human NKG2D-L is also regulated by protein turnover and that the brief residence of ULBP1 could contribute to the fine tuning of immune responses.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26732147     DOI: 10.1038/icb.2016.2

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  46 in total

1.  Inositol deacylation by Bst1p is required for the quality control of glycosylphosphatidylinositol-anchored proteins.

Authors:  Morihisa Fujita; Takehiko Yoko-O; Yoshifumi Jigami
Journal:  Mol Biol Cell       Date:  2005-11-30       Impact factor: 4.138

2.  BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia.

Authors:  Nicolas Boissel; Delphine Rea; Vannary Tieng; Nicolas Dulphy; Manuel Brun; Jean-Michel Cayuela; Philippe Rousselot; Ryad Tamouza; Philippe Le Bouteiller; François-Xavier Mahon; Alexander Steinle; Dominique Charron; Hervé Dombret; Antoine Toubert
Journal:  J Immunol       Date:  2006-04-15       Impact factor: 5.422

3.  Human microRNAs regulate stress-induced immune responses mediated by the receptor NKG2D.

Authors:  Noam Stern-Ginossar; Chamutal Gur; Moshe Biton; Elad Horwitz; Moran Elboim; Noa Stanietsky; Michal Mandelboim; Ofer Mandelboim
Journal:  Nat Immunol       Date:  2008-09       Impact factor: 25.606

4.  A second lineage of mammalian major histocompatibility complex class I genes.

Authors:  S Bahram; M Bresnahan; D E Geraghty; T Spies
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-05       Impact factor: 11.205

5.  Cutting edge: the metalloproteinase ADAM17/TNF-alpha-converting enzyme regulates proteolytic shedding of the MHC class I-related chain B protein.

Authors:  Philippe Boutet; Sonia Agüera-González; Susan Atkinson; Caroline J Pennington; Dylan R Edwards; Gillian Murphy; Hugh T Reyburn; Mar Valés-Gómez
Journal:  J Immunol       Date:  2009-01-01       Impact factor: 5.422

6.  ULBP6/RAET1L is an additional human NKG2D ligand.

Authors:  Robert A Eagle; James A Traherne; James R Hair; Insiya Jafferji; John Trowsdale
Journal:  Eur J Immunol       Date:  2009-11       Impact factor: 5.532

7.  Retention and degradation of proteins containing an uncleaved glycosylphosphatidylinositol signal.

Authors:  M C Field; P Moran; W Li; G A Keller; I W Caras
Journal:  J Biol Chem       Date:  1994-04-08       Impact factor: 5.157

8.  Proteasome regulation of ULBP1 transcription.

Authors:  James E Butler; Mikel B Moore; Steven R Presnell; Huei-Wei Chan; N Jan Chalupny; Charles T Lutz
Journal:  J Immunol       Date:  2009-05-15       Impact factor: 5.422

Review 9.  Brefeldin A: insights into the control of membrane traffic and organelle structure.

Authors:  R D Klausner; J G Donaldson; J Lippincott-Schwartz
Journal:  J Cell Biol       Date:  1992-03       Impact factor: 10.539

10.  Posttranslational regulation of the NKG2D ligand Mult1 in response to cell stress.

Authors:  Timothy J Nice; Laurent Coscoy; David H Raulet
Journal:  J Exp Med       Date:  2009-01-26       Impact factor: 14.307

View more
  7 in total

Review 1.  Paleoproteomics.

Authors:  Christina Warinner; Kristine Korzow Richter; Matthew J Collins
Journal:  Chem Rev       Date:  2022-07-15       Impact factor: 72.087

2.  Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition.

Authors:  Aroa Baragaño Raneros; Alfredo Minguela; Ramon M Rodriguez; Enrique Colado; Teresa Bernal; Eduardo Anguita; Adela Vasco Mogorron; Alberto Chaparro Gil; Jose Ramon Vidal-Castiñeira; Leonardo Márquez-Kisinousky; Paula Díaz Bulnes; Amelia Martinez Marin; Maria Carmen García Garay; Beatriz Suarez-Alvarez; Carlos Lopez-Larrea
Journal:  Oncotarget       Date:  2017-05-09

Review 3.  NKG2D and Its Ligands: "One for All, All for One".

Authors:  Alessandra Zingoni; Rosa Molfetta; Cinzia Fionda; Alessandra Soriani; Rossella Paolini; Marco Cippitelli; Cristina Cerboni; Angela Santoni
Journal:  Front Immunol       Date:  2018-03-12       Impact factor: 7.561

Review 4.  Post-translational Mechanisms Regulating NK Cell Activating Receptors and Their Ligands in Cancer: Potential Targets for Therapeutic Intervention.

Authors:  Rosa Molfetta; Alessandra Zingoni; Angela Santoni; Rossella Paolini
Journal:  Front Immunol       Date:  2019-10-31       Impact factor: 7.561

5.  Cell-mediated immune resistance in cancer.

Authors:  Yuhao Wang; Emily Hays; Martina Rama; Benjamin Bonavida
Journal:  Cancer Drug Resist       Date:  2020-01-02

Review 6.  Glycosyl-Phosphatidyl-Inositol (GPI)-Anchors and Metalloproteases: Their Roles in the Regulation of Exosome Composition and NKG2D-Mediated Immune Recognition.

Authors:  Sheila López-Cobo; Carmen Campos-Silva; Mar Valés-Gómez
Journal:  Front Cell Dev Biol       Date:  2016-09-12

Review 7.  NKG2D Ligands-Critical Targets for Cancer Immune Escape and Therapy.

Authors:  Dominik Schmiedel; Ofer Mandelboim
Journal:  Front Immunol       Date:  2018-09-11       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.